Skip to main content
. 2015 Jul 15;10(7):e0130796. doi: 10.1371/journal.pone.0130796

Fig 3. Novel activities for selected approved drugs versus specified assay modules.

Fig 3

A. Potentiation of Wnt pathway signaling by rotenone. Included are the outcomes in a multilineage potential C2C12 cell line as judged by β-catenin translocation (□) and alkaline phosphatase activity (Δ); selectivity of the Wnt response vs. cell cycle effects is assessed by comparison to % inhibition of cell count (■) and % stimulation of 4N DNA content (●) as determined via propidium iodide staining in HeLa cells. B. Potentiation of Wnt pathway signaling by antifolates methotrexate (●), pyrimethamine (■), metoprine (Bw 197U; Δ), trimetrexate (□) and raltitrexed (∇) in the Wnt potentiation module. C. In vitro anti-angiogenic activity of cetaben. Inhibition of tube area in ECFC as measured via CD31 staining (▲) in the absence of ECFC/ADSC cytoxicity as assessed via Hoechst staining (■); selectivity of endothelial response vs. cell cycle effects is assessed by comparison to % inhibition of cell count (●) and % stimulation of 4N DNA content (□) as determined via propidium iodide staining in HeLa cells.